Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.…
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics (NASDAQ: OBX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 12.00 USD on 20 November 2026. Its 52-week range is 9.600 USD to 49.97 USD: the price is 76.0% below the high and 25.0% above the low.
Its market capitalisation is 741.29M USD.
Obsidian Therapeutics reports return on equity of 37.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 31.54M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 38.67 USD is 222.2% above the current price.